Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Puma Biotechnology Inc’s stock clocked out at $4.95, down -0.60% from its previous closing price of $4.98. In other words, the price has decreased by -$0.60 from its previous closing price. On the day, 0.59 million shares were traded. PBYI stock price reached its highest trading level at $5.08 during the session, while it also had its lowest trading level at $4.885.
Ratios:
To gain a deeper understanding of PBYI’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.82. For the most recent quarter (mrq), Quick Ratio is recorded 1.62 and its Current Ratio is at 1.74. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.04.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’25 when MILLER MICHAEL PATRICK sold 20,000 shares for $4.86 per share. The transaction valued at 97,228 led to the insider holds 54,000 shares of the business.
MILLER MICHAEL PATRICK bought 20,000 shares of PBYI for $97,228 on Nov 11 ’25. On Jul 18 ’25, another insider, Cesano Alessandra, who serves as the Director of the company, sold 27,000 shares for $3.37 each. As a result, the insider received 90,909 and left with 41,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 249435968 and an Enterprise Value of 196099984. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.68, and their Forward P/E ratio for the next fiscal year is 11.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.18 while its Price-to-Book (P/B) ratio in mrq is 2.16. Its current Enterprise Value per Revenue stands at 0.925 whereas that against EBITDA is 4.389.
Stock Price History:
The Beta on a monthly basis for PBYI is 1.16, which has changed by 0.5417956 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, PBYI has reached a high of $6.12, while it has fallen to a 52-week low of $2.58. The 50-Day Moving Average of the stock is -2.13%, while the 200-Day Moving Average is calculated to be 26.35%.
Shares Statistics:
It appears that PBYI traded 548.81K shares on average per day over the past three months and 557790 shares per day over the past ten days. A total of 50.38M shares are outstanding, with a floating share count of 38.19M. Insiders hold about 24.21% of the company’s shares, while institutions hold 60.29% stake in the company. Shares short for PBYI as of 1763078400 were 3332897 with a Short Ratio of 6.09, compared to 1760486400 on 3360938. Therefore, it implies a Short% of Shares Outstanding of 3332897 and a Short% of Float of 7.7299999999999995.
Earnings Estimates
. The current rating of Puma Biotechnology Inc (PBYI) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.69 and $0.69 for the fiscal current year, implying an average EPS of $0.69. EPS for the following year is $0.55, with 1.0 analysts recommending between $0.55 and $0.55.
Revenue Estimates
In . The current quarter, 1 analysts expect revenue to total $68.6M. It ranges from a high estimate of $68.6M to a low estimate of $68.6M. As of . The current estimate, Puma Biotechnology Inc’s year-ago sales were $59.1MFor the next quarter, 1 analysts are estimating revenue of $49M. There is a high estimate of $49M for the next quarter, whereas the lowest estimate is $49M.
A total of 1 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $221.5M, while the lowest revenue estimate was $221.5M, resulting in an average revenue estimate of $221.5M. In the same quarter a year ago, actual revenue was $230.5MBased on 1 analysts’ estimates, the company’s revenue will be $220M in the next fiscal year. The high estimate is $220M and the low estimate is $220M.
